Biogen Idec received approval from the European Commission for its Avonex Pen for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event. Avonex Pen is the first single-use, once-a-week, integrated intramuscular autoinjector available for use with Avonex treatment in patients with relapsing MS. The company designed Avonex Pen to improve convenience of administration by simplifying the injection and supporting patient independence. “At Biogen Idec...